The cost effectiveness of tamoxifen in the prevention of breast cancer

American Journal of Managed Care

Volumn 5, Issue 6 SUPPL., 1999, Pages

  Noe, Les L ^a   Becker III, Russell V ^a   Gradishar, William J ^b   Gore, Mugdha ^c   Trotter, Jeffrey P ^a  

^a Ovation Research Group   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HUMAN; HYSTERECTOMY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME; UNITED STATES;

EID: 0033024932     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute; 1998.
2. Breast Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 1998.
3. Wakeling AE, Valcaccia B, Newboult E, et al. Non-steroidal antioestrogens: Receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984;20:111-120.
4. Dao TL. The role of ovarian hormones in initiating the induction of mammary cancer in rats by polynuclear hydrocarbons. Cancer Res 1962;22:973-981.
5. Briziarelli G. Effects of dosage and time of administration of testosterone propionate on 7, 12-dimethylbenzanthracene mammary carcinogenesis in the rat. Z Krebsforsch 1965;66:517-522.
6. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987;47:4517-4519.
7. Terenius L. Effect of anti-oestrogens on initiation of mammary cancer in the female rat. Eur J Cancer 1971;7:65-70.
8. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12:419-424.
9. Jordan VC, Dix CJ, Allen KE. The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Jones SE, Salmon SE, eds. Adjuvant Therapy of Cancer II. New York, NY: Grune and Stratton; 1979:19-26.
10. Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-251.
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials, Lancet 1998;351:1451-1467.
12. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
13. Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987;2:171 -175.
14. Rutqvist LE, Cedermark B, Glas U, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer: Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987;10:255-266.
15. Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-1306.
16. Abram WP, Baum M, Berstock DA, et al. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer: Preliminary analysis by the CRC Adjuvant Breast Trial Working Party. Br J Cancer 1988;57:604-607.
17. Fisher B, Redmond C. New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991;83:1278-1280.
18. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
19. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
20. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994;31:73-82.
21. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-97.
22. Powles T, Eeles R, Asbley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
23. Vanchieri C. Breast cancer prevention study initiated in Italy. J Natl Cancer Inst 1992;84:1555-1556.
24. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998;352:80-81.
25. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984;52:339-346.
26. Bertelli G, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307-310.
27. Bruning PF, Bonfrer JM, Hart AA, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497-499.
28. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl. Cancer Inst 1990;82:1327-1332.
29. Bagdade JD, Wolter J, Subbaiah PV, et al. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132-1135.
30. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-864.
31. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br Med J 1995;311:977-980.
32. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
33. Fornander T, Rutqvist LE, Sjoberg HE, et al. Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 1990;8:1019-1024.
34. Cuzick J, Allen D, Baum M, et al. Long-term effects of tamoxifen. Eur J Cancer 1993;22:87-94.
35. Neal AJ, Evans K, Hoskin PJ. Does long-term administration of tamoxifen affect bone mineral density? Eur J Cancer 1993;29A: 1971-1973.
36. Turken S, Siris E, Seldin D, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81:1086-1088.
37. Ward RL, Morgan G, Dalley D, et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993;22:87-94.
38. Rutqvist LE, Johansson H, Signomklao T, et al, for the Stockholm Breast Cancer Study Group. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-651.
39. Rutqvist LE, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials. Int J Radiation Oncology Biol Phys 1989;16:629-639.
40. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
41. Fisher B. A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 1996;14:1027-1039.
42. Assikis VJ, Neven P, Jordan VC, et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-1476.
43. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-426.
44. Muñoz E, Shamash F, Friedman M, et al. Lumpectomy vs mastectomy: The costs of breast preservation for cancer. Arch Surg 1986;121:1297-1301.
45. Legorreta AP, Brooks RJ, Leibowitz AN, et al. Cost of breast cancer treatment: A 4-year longitudinal study. Arch Intern Med 1996;156:2197-2201.
46. Elixhauser A. Costs of breast cancer and the cost-effectiveness of breast cancer screening. Intl J Tech Assess Health Care 1991;7:604-615.
47. Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of breast and lung cancer. Med Care 1991;29:40-49.
48. Carter AP, Thompson RS, Bourdeau RV, et al. A clinically effective breast cancer screening program can be cost-effective too. Prev Med 1987;16:19-34.
49. Greenwood M, Henritze J. Coorscreen: A low-cost, on-site mammography screening program. Am J Health Promot 1996; 10:364-370.
50. Brown ML. The national economic burden of cancer: An update. J Natl Cancer Inst 1990;82:1811-1814.
51. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-168.
52. Hillner BE, Smith TJ. Should women with node-negative breast cancer receive adjuvant chemotherapy? Insights from a decision analysis model. Breast Cancer Res Treat 1992;23:17-27.
53. Bryson HM, Plosker GL. Tamoxifen: A review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer. Pharmacoeconomics 1993;4:40-66.
54. Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat 1993;25:97-105.
55. Desch CE, Hillner BE, Smith TJ, et al. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993;11:777-782.
56. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:1460-1474.
57. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9(suppl 2):8-22.
58. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996;23 (1 suppl 2):43-50.
59. Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: A suggested framework. Value in Health 1998;1:131-147.
60. TreeAge Software, Inc, Williamstown, MA.
61. US Department of Health and Human Services. Vital Statistics of the United States, 1991, Volume II Mortality Data, Part A. Hyattsville, MD: USDHHS; 1996:14-111.
62. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
63. Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-251.
64. Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. Cancer 1995;76:237-242.
65. Robinson CM, Court-Brown CM, McQueen MM, et al. Hip fractures in adults younger than 50 years of age. Clin Orth Rel Res 1995;312:238-246.
66. Magaziner J, Lydick E, Hawkes W, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997;87:1630-1636.
67. Hu R, Mustard CA, Burns C. Epidemiology of incident spinal fracture in a complete population. Spine 1996;21:492-499.
68. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-462.
69. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-1466.
70. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
71. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276: 1339-1341.
72. Fuchs VR, Zeckhauser R. Valuing health: A "priceless" commodity. Am Econ Rev 1987;77:263-268.
73. Lipscomb J, Weinstein MC, Torrance GW. 1996: Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:214-246.
74. Hillman AL, Kim MS. Economic decision making in healthcare: A standard approach to discounting health outcomes. Pharmacoeconomics 1995;7:198-205.
75. Mushinski M. Hysterectomy charges: Geographic variations United States, 1994. Stat Bull 1996;77:2-12.
76. Spirtos NM, Schlaerth JB, Gross GM, et al. Cost and quality-of-life analyses of surgery for early endometrial cancer: Laparotomy versus laparoscopy. Am J Obstet Gynecol 1996;174:1795-1800.
77. Dorsey JH, Holtz PM, Griffiths RI, et al. Costs and charges associated with three alternative techniques of hysterectomy. N Engl J Med 1996;335:476-482.
78. Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-764.
79. Perrier A, Buswell L, Bounameaux H, et al. Cost-effectiveness of noninvasive diagnostic aids in suspected pulmonary embolism. Arch Int Med 1997;157:2309-2316.
80. Steinberg EP, Javitt JC, Sharkey PD, et al. The content and cost of cataract surgery. Arch Ophthalmol 1993;111:1041-1049.
81. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994;15:377-386.
82. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: A prospective study. J Am Geriatr Soc 1997;45:281-287.
83. Clancy T, Kitchen S, Churchill P, et al. DRG reimbursement: Geriatric hip fractures in the community hospital trauma center. Southern Med J 1998;91:457-461.
84. Johnell O. The socioeconomic burden of fractures: Today and in the 21st century. Am J Med 1997;103(2A):20S-26S.
85. Kramer AM, Steiner JF, Schlenker RE, et al. Outcomes and costs after hip fracture and stroke: A comparison of rehabilitation settings. JAMA 1997;277:396-404.
86. Barrett-Conner E. The economic and human costs of osteoporotic fracture. Am J Med 1995;98(suppl 2A):3S-8S.
87. Hawkins DW, Langley PC, Krueger KP. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther 1998;20: 182-195.
88. Mushinski M. Variations in average charges for strokes and TIAs: United States, 1995. Stat Bull 1997;78:9-18.
89. Mosby's GenRx, 8th ed. St. Louis, MO: Mosby-Year Book; 1998.
90. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332: 1418-1424.
91. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987;25:25-34.
92. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997; 127:955-965.
93. Plans-Rubio P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease. Pharmacoeconomics 1998;13(Part 2):623-643.